What is OS Therapies's share price?

OS Therapies (OSTX) reported share price of $1.34 in Q2 2025.

What does share price mean?

The share price represents the current market valuation of a single share of the company's common stock as determined by public exchange trading. It serves as a primary indicator of investor sentiment, reflecting the market's assessment of the company's clinical pipeline progress and future commercial potential. This metric is essential for calculating market capitalization and evaluating the cost of equity capital.

OS Therapies OSTX Share Price

Share Price at other companies

Hercules CapitalHTGC

$14.77-23.1%

Bain Capital Specialty FinanceBCSF

$12.40-25.3%

Prospect CapitalPSEC

$25.000.0%

CBAK Energy Technology, Inc.CBAT

$0.95-11.2%

TecnoglassTGLS

$0.150.0%

Laser Photonics CorporationLASE

$2.58—

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:SharePrice.

The official record: OS Therapies’s 10-Q, filed November 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's share price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's share price?: OS Therapies (OSTX) reported share price of $1.34 in Q2 2025.
What does share price mean?: The share price represents the current market valuation of a single share of the company's common stock as determined by public exchange trading. It serves as a primary indicator of investor sentiment, reflecting the market's assessment of the company's clinical pipeline progress and future commercial potential. This metric is essential for calculating market capitalization and evaluating the cost of equity capital.